Table IV.
Input parameters used for model based economic evaluation of implementing Mycobacterium indicus pranii (MIP) vaccination in National Leprosy Eradication Programme (NLEP) India
| Parameters used | Base case | Lower limit | Upper limit | Distribution | Reference number |
|---|---|---|---|---|---|
| Demographical data | |||||
| Life expectancy at age 27 (yr) | 44.75 | 33.56 | 55.93 | NA | 30 |
| Average age of leprosy patient at diagnosis (yr) | 27 | 20.25 | 33.75 | NA | 31 |
| Epidemiological parameters | |||||
| New leprosy patients in 2016-2017 | 135,485 | 101,614 | 169,356 | NA | 33 |
| Contacts per new patient | 20 | 6 | 25 | NA | 25 35 |
| Contacts in 2016-2017 | 2,709,700 | 609,684 | 4,233,900 | NA | 32 |
| Incidence of leprosy in the population | |||||
| Incidence in contacts 2016-2017 | 0.0008 | 0.0006 | 0.0010 | Beta | 32 |
| Incidence in general population 2016-2017 | 0.00010 | 0.00007 | 0.00012 | Beta | 32 |
| Vaccine effect used in the study | |||||
| Vaccine efficacy | 0.60 | 0.45 | 0.75 | Beta | 9 10 |
| Disability rate | |||||
| Proportion of leprosy patients getting disability | 0.04 | 0.03 | 0.05 | Beta | 43 44 |
| Mortality | |||||
| Mortality due to leprosy | 0.089500 | 0.067125 | 0.111875 | Beta | 35 |
| Quality of Life (QoL) | |||||
| QoL of healthy Indian | 1 | 1 | 1 | Beta | Assumption |
| QoL of leprosy patient | 0.848 | 0.636 | 1 | Beta | 34 |
| QoL of leprosy patient with disability | 0.6021 | 0.451575 | 0.752625 | Beta | 33 |
| Relapses in patients in percentage | |||||
| Relapse rate | 0.02 | 0.015 | 0.025 | NA | 30 32 |
| Costs/expenses estimated in Indian rupees | |||||
| Cost of vaccinating per person | 96.6 | 72.45 | 120.75 | Gamma | Table III |
| Cost of leprosy treatment (health system) | 14,000 | 10,000 | 36,000 | Gamma | 38 |
| Cost of leprosy treatment (patient) | 10,680 | 8010 | 13,350 | Gamma | 39 |
| Cost of treatment (health system perspective) | 24,680 | 18,010 | 49,350 | Gamma | 32 |
| Cost of foot wear | 1400 | 1080 | 1800 | Gamma | 32 |
| Expenses incurred for RCS | 5142 | 3856 | 6427 | Gamma | 32 |
| Incentives to health workers | 750 | 563 | 938 | Gamma | 32 |
| Discounting rate as used in the study | |||||
| Discounting rate (costs) | 0.03 | 0.03 | 0.03 | Beta | 40 |
| Discounting rate (QoL) | 0.03 | 0.03 | 0.03 | Beta | 40 |
| CET (Cost effectiveness thresholds) | |||||
| Per capita in Indian rupees GDP India 2018 | 120,000 | 120,000 | 120,000 | NA | 42 |
QoL, quality of life; CET, cost-effectiveness thresholds; RCS, reconstructive surgery; GDP, gross domestic product